Continuous glucose monitor coverage has expanded considerably beyond its original focus on intensive insulin therapy for type 1 diabetes, reflecting accumulating evidence of benefit across a broader diabetes population — but real, documented access gaps remain, and understanding the current coverage landscape clarifies where genuine barriers still limit appropriate technology access.
Medicare Coverage Criteria Have Broadened Considerably Over Time
Medicare CGM coverage, historically restricted to beneficiaries on intensive insulin therapy meeting specific testing frequency requirements, has broadened over successive policy updates to cover a wider population, including some beneficiaries on basal insulin alone rather than requiring multiple daily injections or insulin pump therapy — this expansion reflects accumulating evidence that CGM benefit extends meaningfully beyond the originally covered population, though beneficiaries and prescribers still need to verify current specific coverage criteria given that policy continues to evolve.
State Medicaid Programs Show Considerable Variation
Unlike the more uniform national Medicare framework, state Medicaid CGM coverage policies vary considerably, with some states offering coverage closely aligned with expanded Medicare criteria and others maintaining more restrictive requirements — this state-level variation means a patient's actual CGM access can depend significantly on which state's Medicaid program covers them, an equity consideration that has drawn attention from diabetes advocacy organizations pushing for more consistent coverage standards across states.
Commercial Insurance Coverage Has Generally Followed Similar Broadening Trends
Most commercial insurance plans have similarly broadened CGM coverage criteria over time, though prior authorization requirements, specific documentation burdens, and formulary preferences for particular CGM brands over others continue to create friction that can delay or complicate access even for patients who ultimately qualify under the plan's coverage criteria — this administrative friction represents a distinct barrier from outright coverage denial, but one that meaningfully affects real-world access timeline nonetheless.
Type 2 Diabetes Coverage Remains More Restrictive Than for Type 1
Despite growing evidence supporting CGM benefit for type 2 diabetes patients, including those not on intensive insulin therapy, coverage criteria for this population generally remain more restrictive than for type 1 diabetes or intensive insulin therapy patients — this reflects both a genuinely still-accumulating (if increasingly supportive) evidence base for broader type 2 CGM use and payer cost considerations given the much larger overall type 2 diabetes population relative to type 1.
Over-the-Counter CGM Options Have Created a Parallel Access Pathway
The emergence of over-the-counter CGM products, available without a prescription for general wellness use, has created a coverage-independent access pathway for patients who do not meet prescription CGM coverage criteria but wish to use the technology — though this pathway generally requires out-of-pocket payment, since over-the-counter products are typically not eligible for the same insurance coverage prescription CGM devices can access, meaning this parallel pathway addresses a different access barrier than the one facing patients seeking prescription-covered CGM use.
Documentation and Prior Authorization Burden Falls Disproportionately on Prescribers
Navigating CGM coverage, including prior authorization documentation and periodic renewal requirements, creates meaningful administrative burden for prescribing clinicians, and some practices have found this burden itself a barrier to consistently offering CGM to eligible patients, independent of the underlying coverage policy's actual generosity — streamlining this administrative process has been a focus of some payer and provider organization collaboration efforts specifically aimed at reducing this friction.
Conclusion
CGM insurance coverage has expanded meaningfully beyond its original narrow population, though state Medicaid variation, type 2 diabetes coverage restrictions, and administrative prior authorization burden remain genuine, documented access gaps. Facilities and patients navigating this landscape depend on reliable access to diabetes monitoring supplies across whatever coverage pathway ultimately applies.
